Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.105 USD | -.--% | -.--% | -.--% |
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Cordyceps Related Products
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -45.01% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Taiwan and Hong Kong
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -45.01% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Pao Chi Chu
CEO | Chief Executive Officer | 70 | 29/01/17 |
Shi Ming Li
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jer Li Lin
CTO | Chief Tech/Sci/R&D Officer | - | - |
Shi Tao Li
CTO | Chief Tech/Sci/R&D Officer | - | - |
Cheng Hsiang Kao
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Pao Chi Chu
CEO | Chief Executive Officer | 70 | 29/01/17 |
Cheng Hsiang Kao
PRN | Corporate Officer/Principal | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 60,042,000 | 30,042,000 ( 50.03 %) | 0 | 50.03 % |
Company contact information
Acro Biomedical Co. Ltd.
12175 Visionary Way Suite 1160
46038, Fishers
+
Sector
1st Jan change | Capi. | |
---|---|---|
-.--% | 6.3M | |
+17.39% | 8.62B | |
+6.26% | 7.68B | |
+7.55% | 6.38B | |
-7.57% | 3.74B | |
-5.10% | 3.71B | |
-1.78% | 1.34B | |
-27.65% | 1.12B | |
+18.29% | 1.05B | |
-9.30% | 913M |
- Stock Market
- Equities
- ACBM Stock
- Company Acro Biomedical Co., Ltd.